TICKERNOMICS Sign up
Last Update: 2023-12-23 06:00:47
Avidity Biosciences Inc. ( RNA ) https://www.aviditybiosciences.com
9.08USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-56.56%
RNA
SPY
30.72%
-69.83%
RNA
SPY
112.82%
RNA
0.00%
SPY
201.04%
RNA
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
649.09
202.74
0.73
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-3.34
64.04
1.25
-23.87
0.00
-0.92
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-2080.38
100.00
-2176.44
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-62.26
-45.22
0.00
Other Earnings and Cash Flow Stats:
Avidity Biosciences Inc. ( RNA ) Net Income TTM ($MM) is -189.54
Avidity Biosciences Inc. ( RNA ) Operating Income TTM ($MM) is -209.56
Avidity Biosciences Inc. ( RNA ) Owners' Earnings Annual ($MM) is 0.00
Avidity Biosciences Inc. ( RNA ) Current Price to Owners' Earnings ratio is 0.00
Avidity Biosciences Inc. ( RNA ) EBITDA TTM ($MM) is -213.06
Avidity Biosciences Inc. ( RNA ) EBITDA Margin is -2176.44%
Capital Allocation:
Avidity Biosciences Inc. ( RNA ) has paid 0.00 dividends per share and bought back -21.028 million shares in the past 12 months
Avidity Biosciences Inc. ( RNA ) has reduced its debt by 0.694 million USD in the last 12 months
Capital Structure:
Avidity Biosciences Inc. ( RNA ) Interest-bearing Debt ($MM) as of last quarter is 10
Avidity Biosciences Inc. ( RNA ) Annual Working Capital Investments ($MM) are -43
Avidity Biosciences Inc. ( RNA ) Book Value ($MM) as of last quarter is 517
Avidity Biosciences Inc. ( RNA ) Debt/Capital as of last quarter is 2%
Other Balance Sheet Stats:
Avidity Biosciences Inc. ( RNA ) has 85 million in cash on hand as of last quarter
Avidity Biosciences Inc. ( RNA ) has 48 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Avidity Biosciences Inc. ( RNA ) has 74 common shares outstanding as of last quarter
Avidity Biosciences Inc. ( RNA ) has 0 million USD of preferred stock value
Academic Scores:
Avidity Biosciences Inc. ( RNA ) Altman Z-Score is 5.57 as of last quarter
Avidity Biosciences Inc. ( RNA ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Avidity Biosciences Inc. ( RNA ) largest shareholder is Vanguard Group Inc owning 3967185 shares at 36.02 ($MM) value
Arthur A Levin(an insider) Sold 10000 shares of Avidity Biosciences Inc. ( RNA ) for the amount of $236600.00 on 2023-02-14
4.56% of Avidity Biosciences Inc. ( RNA ) is held by insiders, and 108.39% is held by institutions
Avidity Biosciences Inc. ( RNA ) went public on 2013-06-28
Other Avidity Biosciences Inc. ( RNA ) financial metrics:
FCF:-160.61
Unlevered Free Cash Flow:0.00
EPS:-2.83
Operating Margin:-2080.38
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-40.47
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Avidity Biosciences Inc. ( RNA ) :
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.